These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9350248)

  • 21. [Effects of single administration of tetrahydropyranyladriamycin (THP) in lymphoid malignancy].
    Takagi T; Oguro M; Iwabuchi K
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1450-6. PubMed ID: 6588924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
    Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
    Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
    Kim RJ; Peterson G; Kulp B; Zanotti KM; Markman M
    Gynecol Oncol; 2005 May; 97(2):374-8. PubMed ID: 15863132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
    Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM
    Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
    Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].
    Nagao S; Okimoto N; Hongo A; Mizutani Y; Kodama J; Yoshinouchi M; Hiramatsu Y; Kudo T
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):243-9. PubMed ID: 12610873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity.
    Chlebowski RT; Paroly WS; Pugh RP; Hueser J; Jacobs EM; Pajak TF; Bateman JR
    Cancer Treat Rep; 1980 Jan; 64(1):47-51. PubMed ID: 7379058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?
    Köseoğlu V; Berberoğlu S; Karademir S; Kismet E; Yurttutan N; Demirkaya E; Sungur M; Alehan D
    Turk J Pediatr; 2005; 47(1):17-22. PubMed ID: 15884624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
    Saad SY; Najjar TA; Alashari M
    J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of 4'-O-tetrahydropyranyl-doxorubicin on isolated perfused rat heart and cardiac mitochondrial cytochrome C oxidase activity.
    Del Tacca M; Danesi R; Solaini G; Bernardini M; Bertelli A
    Anticancer Res; 1987; 7(4B):803-6. PubMed ID: 2823684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trials of tetrahydropyranyl-adriamycin (Pirarubicin) on renal and colon carcinoma, melanoma, and soft tissue sarcoma.
    Roché H; Guiochet N; Kerbrat P; Rebattu P; Fargeot P; Cattan A; Armand JP; Keiling R; Lentz MA; Van Glabeke M
    Am J Clin Oncol; 1993 Apr; 16(2):137-9. PubMed ID: 8452105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adriamycin cardiotoxicity: a survey of 1273 patients.
    Praga C; Beretta G; Vigo PL; Lenaz GR; Pollini C; Bonadonna G; Canetta R; Castellani R; Villa E; Gallagher CG; von Melchner H; Hayat M; Ribaud P; De Wasch G; Mattsson W; Heinz R; Waldner R; Kolaric K; Buehner R; Ten Bokkel-Huyninck W; Perevodchikova NI; Manziuk LA; Senn HJ; Mayr AC
    Cancer Treat Rep; 1979 May; 63(5):827-34. PubMed ID: 455324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].
    Kuroda K; Ishii N; Fukasawa K; Shirai M; Tajima M; Matsushima M; Miura K; Takanami M; Matsuhashi M; Kuwabara T; Matsumoto H; Sugita M
    Hinyokika Kiyo; 1998 Aug; 44(8):547-52. PubMed ID: 9783189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
    Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G
    J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [THP-adriamycin in head and neck tumor].
    Honda T; Ohyama W; Sonoda T; Uchida K; Hirokawa T; Takada K; Takeda C
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2538-44. PubMed ID: 6651307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Local administration of adriamycin (ADM) for malignant pleural effusion and pericardiac effusion in breast cancer].
    Saisho S; Saeki T; Takashima S; Aogi K; Ohsumi S
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2063-8. PubMed ID: 14712766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.